Anterior Uveitis Secondary to Intravitreal Bevacizumab Injection: A Case Report
- 26 March 2026
- journal article
- Published by Saglik Bilimleri Universitesi in İzmir Tıp Fakültesi Dergisi
- Vol. 5 (1) , 31-36
Abstract
Objective: To present the clinical features and follow-up of a case of anterior uveitis secondary to intravitreal bevacizumab injection. Case Presentation: A 73 year old female patient, under follow-up in our retina unit for neovascular age-related macular degeneration (AMD), presented with complaints of pain and decreased vision in the left eye that started 13 days after an intravitreal bevacizumab injection. On ophthalmologic examination, best corrected visual acuity was 1.5 logMAR in the right eye and 2.3 logMAR in the left eye. Intraocular pressure (IOP) was measured as 20 mmHg in the right eye and 40 mmHg in the left eye. Biomicroscopic examination revealed a normal anterior segment in the right eye, while in the left eye, granulomatous keratic precipitates were observed in the inferoparacentral cornea, along with +3 flare in the anterior chamber. Pseudoexfoliation was present; the pupillary margins were regular, and posterior synechiae were not detected. Dilated fundus examination revealed a scar consistent with senile macular degeneration in the right eye, while the retina appeared hazy in the left eye. Ocular ultrasonography demonstrated an attached retina in the left eye without vitreous reaction. The patient was evaluated as anterior uveitis secondary to intravitreal bevacizumab injection and was hospitalized for follow-up and treatment. Topical corticosteroid and anti-glaucomatous therapy were initiated, leading to regression of findings, and the patient was followed up for 3 months. Conclusion: Anterior uveitis secondary to intravitreal bevacizumab injection is a rare complication. Endophthalmitis should always be considered in the differential diagnosis, and in appropriate cases, successful outcomes can be achieved with topical corticosteroid therapy. Keywords: Anti-vascular endothelial growth factor (anti-VEGF), anterior uveitis, bevacizumab, intraocular inflammationKeywords
This publication has 11 references indexed in Scilit:
- Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative reviewInternational Journal of Retina and Vitreous, 2021
- Inflammatory Complications of Intravitreal Anti-VEGF InjectionsJournal of Clinical Medicine, 2021
- Distinguishing Between Infectious Endophthalmitis and Noninfectious Inflammation Following Intravitreal Anti-VEGF InjectionJournal of Vitreoretinal Diseases, 2018
- Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular DegenerationOphthalmology, 2018
- Intraocular Inflammation Following Intravitreal Injection of Anti-VEGF Medications for Neovascular Age-Related Macular DegenerationOphthalmic Epidemiology, 2016
- Ocular inflammation associated with antivascular endothelial growth factor treatmentCurrent Opinion in Ophthalmology, 2015
- Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complicationClinical Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumabClinical Ophthalmology, 2011
- Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2008